Early action, lifelong impact: the crucial role of early detection, risk stratification, and aggressive treatment of familial hypercholesterolaemia
- PMID: 38376464
- DOI: 10.1093/eurjpc/zwae068
Early action, lifelong impact: the crucial role of early detection, risk stratification, and aggressive treatment of familial hypercholesterolaemia
Conflict of interest statement
Conflict of interest: W.K. reports advisory board fees from AstraZeneca, Novartis, Amgen, Pfizer, The Medicines Company, DalCor, Kowa, Corvidia, OMEICOS, Daiichi-Sankyo, Novo Nordisk, New Amsterdam Pharma, TenSixteen Bio, Esperion, Genentech; lecture fees from Bristol-Myers Squibb, Novartis, Amgen, Berlin-Chemie, Sanofi and AstraZeneca; grants and non-financial support from Abbott, Roche Diagnostics, Beckmann, and Singulex, outside the submitted work. V.S. reports lecture fees from Novartis, Daiichi-Sankyo, and Amgen. R.S.S. has no conflict of interest.
Comment on
-
Beyond early LDL cholesterol lowering to prevent coronary atherosclerosis in familial hypercholesterolaemia.Eur J Prev Cardiol. 2024 May 11;31(7):892-900. doi: 10.1093/eurjpc/zwae028. Eur J Prev Cardiol. 2024. PMID: 38243822
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources